 Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson Johnson JNJ, to discover antibody-drug conjugates ADCs for three targets. Get the Inside Access Traders Are Using to Profit More and Win Bigger. 